Portal de Periódicos da CAPES

Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ

2011; Elsevier BV; Volume: 202; Issue: 1 Linguagem: Inglês

10.1016/j.amjsurg.2010.09.032

1879-1883

Tomohiro Miyake, Kenzo Shimazu, Hiroshi Ohashi, Tetsuya Taguchi, Satsuki Ueda, Takahiro Nakayama, Seung Jin Kim, Katsuyuki Aozasa, Yasuhiro Tamaki, Shinzaburo Noguchi,

Cancer and Skin Lesions

Background The use of sentinel lymph node biopsy (SLNB) for ductal carcinoma in situ (DCIS) is controversial. Methods A total of 103 primary breast cancer patients who were diagnosed with DCIS by needle biopsy preoperatively and underwent initial SLNB were analyzed retrospectively. Results No sentinel nodal metastasis was detected in 66 patients with the final diagnosis of DCIS. However, 2 (5.4%) of 37 patients with invasive ductal carcinoma at final diagnosis had positive sentinel nodes. Multivariate logistic regression analysis identified 2 independent significant predictors of existence of invasive components: presence of a palpable tumor (odds ratio, 4.091; 95% confidential interval, 1.399–11.959; P = .010) and tumor size of 2.0 cm or larger on magnetic resonance imaging (odds ratio, 4.506; 95% confidence interval, 1.322–15.358; P = .016). Conclusions Initial SLNB should be considered for patients diagnosed with DCIS by needle biopsy when they have a high risk for harboring invasive ductal cancer preoperatively.